Dr John Francis Womelsdorf Net Worth

The estimated Net Worth of Dr John Francis Womelsdorf is at least $2.29 Mille dollars as of 18 March 2008. Dr Womelsdorf owns over 5,000 units of Cyclacel Pharmaceuticals Inc stock worth over $2,289 and over the last 18 years Dr sold CYCC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dr Womelsdorf CYCC stock SEC Form 4 insiders trading

Dr has made over 1 trades of the Cyclacel Pharmaceuticals Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Dr bought 5,000 units of CYCC stock worth $14,450 on 18 March 2008.

The largest trade Dr's ever made was buying 5,000 units of Cyclacel Pharmaceuticals Inc stock on 18 March 2008 worth over $14,450. On average, Dr trades about 714 units every 0 days since 2006. As of 18 March 2008 Dr still owns at least 2,100 units of Cyclacel Pharmaceuticals Inc stock.

You can see the complete history of Dr Womelsdorf stock trades at the bottom of the page.

What's Dr Womelsdorf's mailing address?

Dr's mailing address filed with the SEC is 150 JFK PARKWAY, SUITE 100, , SHORT HILLS, NJ, 07078.

Insiders trading at Cyclacel Pharmaceuticals Inc

Over the last 19 years, insiders at Cyclacel Pharmaceuticals Inc have traded over $6,366,241 worth of Cyclacel Pharmaceuticals Inc stock and bought 3,400,245 units worth $14,147,428 . The most active insiders traders include Capital Ltd Portfolio Servi..., Austin W & Greenhouse David... e Kevin Ctang Capital Managem.... On average, Cyclacel Pharmaceuticals Inc executives and independent directors trade stock every 78 days with the average trade being worth of $115,984. The most recent stock trade was executed by Paul Mc Barron on 21 December 2023, trading 1,886 units of CYCC stock currently worth $6,262.

What does Cyclacel Pharmaceuticals Inc do?

cyclacel limited is a pharmaceuticals company located in 46-48 e smithfield, london, united kingdom.

Complete history of Dr Womelsdorf stock trades at Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc executives and stock owners

Cyclacel Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Spiro George Rombotis,
  Pres, CEO & Exec. Director
• Dr. Judy H. Chiao,
  VP of Clinical Devel. & Regulatory Affairs
• Paul McBarron,
  Exec. VP, CFO, COO, Sec. & Exec. Director
• Dr. Mark H. Kirschbaum M.D.,
  Sr. VP & Chief Medical Officer
• Dr. Robert Westwood Ph.D.,
  Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel.
• Gill Christie,
  Director of HR
• Gregory T. Hradsky,
  Director
• Kevin Ctang Capital Managem...,
  
• Judy Chiao,
  V.P., Clin. Dev. & Reg. Aff.
• Nicholas G Bacopoulos,
  Director
• Christopher S Henney,
  Director
• David C Uprichard,
  Director
• Lloyd Sems,
  Director
• Sam L Barker,
  Director
• John Michael Middlecott Banham,
  Director
• Spiro George Rombotis,
  President and CEO
• Capital Ltd Portfolio Servi...,
  
• Robert J. Spiegel,
  Director
• Brian Schwartz,
  Interim Chief Medical Officer
• Daniel K Spiegelman,
  Director
• Austin W & Greenhouse David...,
  10% owner
• Stanley Morgan,
  10% owner
• Robert Edward Sosnowski,
  VP, Marketing & Sales
• James Edeerfield Capital Lp...,
  
• Willian Collins,
  General Manager
• Gregory Reyes,
  Senior VP, Research
• Pierre Legault,
  Director
• John Gordon Mc Vie,
  Director
• Robert Westwood,
  V.P., Chem. & Preclin. Dev.
• Jean Deleage,
  
• Robert Jackson,
  S.V.P. & Chief Scientific Offi
• Mark Kirschbaum,
  Chief Medical Officer
• Paul Mc Barron,
  See Remarks
• Karin L Walker,
  Director
• Kenneth M. Ferguson,
  Director